The BNT162b2 vaccine (Pfizer/BioNTech) has previously shown a 95% efficacy against COVID-19. This efficacy has been changing with the surge of new variants and, at present, its effectiveness against the Omicron variant ─ currently the most prevalent ─ remains unknown. To carry out this study, researchers compared serum samples obtained from participants who had received…
New Evidence in Israel in Favor of Applying a Third Dose against COVID-19
According to this study carried out in Israel, patients over 60 who had received two doses against COVID-19 at least 5 months ago will benefit from an additional dose in terms of a significant reduction of severe disease. In addition, patients who unfortunately got severely ill despite receiving a third shot, were more easily managed. …
Efficacy of the Novavax Vaccine Against COVID-19: Nanoparticle Technology to the Test
In healthy adults, two doses of the NVX-CoV2373 (Novavax) vaccine has an efficacy of almost 90% against SARS-CoV-2 infection in all severity types. Furthermore, it has proven to be effective against the alpha variant (B.1.1.7). The Novavax vaccine is a recombinant nanoparticle containing full-length spike glycoprotein. It had already been shown to be safe and…
Janssen: Efficacy of the Only Single Dose Vaccine against COVID-19
One single dose of the Ad26.COV2.S vaccine (Janssen) will protect you against symptomatic and asymptomatic SARS-CoV-2 infection. It also resulted effective to prevent severe or critical COVID-19, including hospitalization and death. Safety outcomes resulted similar to other COVID-19 vaccine phase 3 outcomes. Janssen vaccine outcomes were published in NEJM 6 months after the first vaccines…
Myocarditis and mRNA COVID-19 Vaccines: New Information from the CDC
According to the CDC (Center for Disease Control and Prevention), even though rare, a relationship between myocarditis and mRNA COVID-19 Vaccines definitely exists. Such risk is more prevalent among men, teenagers and young adults a few days following the second dose. Globally, the risk is low: 4.4 of cases per million after the first dose…
Efficacy of the Sinopharm Vaccine Against COVID-19
Vaccines developed with two different inactivated strains of SARS-CoV-2 (Sinopharm) significantly reduced the risk of symptomatic cases of COVID-19 with an excellent safety profile. Its proven technology—already used against other virus (influenza, hepatitis, polio, rabies)—and the fact that they can be stored at 2-8 °C mean that they are easily (and cheaply) produced, stored, and administered.…
Myocarditis and Messenger RNA COVID-19 Vaccine: What Is the Risk?
European and American agencies (such as the Centers for Disease Control [CDC]) have begun evaluating reports on myocarditis in individuals who received one of the COVID-19 vaccines based on messenger RNA technology (Pfizer/BioNTech and Moderna). This possible association has not been yet established and, even if confirmed in the future, it would not undermine the…
Efficacy of Mass Vaccination with Pfizer/BioNTech against COVID-19 in Israel
We need to know how effective vaccines are by population subgroup outside the controlled setting of a clinical trial. Israel was one of the first countries to deploy a nationwide mass vaccination strategy. This is why it results ideal to compare its results against clinical trial results. All subjects receiving the BNT162b2 mRNA Covid-19 Vaccine…
Findings on Sputnik V Vaccine Against COVID-19
The Sputnik V vaccine was developed by Gamaleya NRCEM. Similarly to the Oxford-AstraZeneca vaccine, it is based on a viral vector, and its findings were published in Lancet. The Russian vaccine comprises two different adenoviruses in the first and the second dose, making it more effective and generating an extended immune response. Both vectors carry…
Safety and Efficacy of the Pfizer-BioNTech Vaccine Against COVID-19
The NEJM has published the efficacy of the COVID-19 vaccine developed by Pfizer and BioNTech, featuring slight differences in the age of enrollment and endpoint definitions compared with other vaccines. Similarly to Moderna‘s, this vaccine is composed of a lipid nanoparticle with modified RNA that encodes a spike glycoprotein covering the surface, modified by two…
- 1
- 2